Schering Corporation

Merck Sharp + Dohme Corp.

Other

Joe F Lee

Pauline C Ting

Richard J Friary

John J Piwinski

Daniel M Solomon

Rongze Kuang

Heping Wu

Jianhua Cao

Vera A Seidl

Jae-Hun Kim

Amjad Ali

Robert G Aslanian

Kevin D McCormick

Dong Xiao

Michael Berlin

Michael Man-Chu Lo

Purakkattle J Biju

Tin-Yau Chan

Wing C Tom

Timothy J Henderson

Yeon-Hee Lim

Tao Yu

Manuel De Lera Ruiz

Jayaram R Tagat

Tanweer A Khan

Yonglian Zhang

Nicolas Zorn

Gang Zhou

Xiaohong Zhu

Frank J Villani

Scott Trzaska

Mary Ann Caplen

John H Schwerdt

Hyunjin M Kim

David Kim

Michael R Reeder

Sylvia Joanna Degrado

Jie Wu

Dhiru B Vashi

Dimitrios Zarkadas

Man Zhu

James P Jakway

Liwu Hong

Kung-I Feng

Luther Williams Lane

David Won-Shik Kim

Chen Mao

Alexander L Tung

Dimitar L Filipov

Dong Won-Shik Kim

Yushi Xiao

Richard Copenhaver

Larry Rainwater

Kevin Boatwright

Roger Whittaker

The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. 

[object Object]

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ('DGAT') inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: 

Inhibitors of diacylglycerol acyltransferase

The present invention relates to the compound of the formula To methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound

Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R.sup.3 is alkyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, cycloalkyl, acyloxymethyl, alkoxy, alkoxymethyl, or alkyl substituted with cycloalkyl; R.sup.4 is H, alkyl, alkenyl, alkoxy, or --OH. Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha. and methods for treating septic shock, inflammation, or allergic disease by administering a compound of Formula I.

Tricyclic derivatives, compositions and methods of use

Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R.sup.4 is alkenyl, alkoxy, or --OH. Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha., and methods for treating septic shock, inflammation, or allergic disease.

Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R.sup.3 is alkyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, cycloalkyl, acyloxymethyl, alkoxy, alkoxymethyl, or alkyl substituted with cycloalkyl;

A binding mechanism for holding yarns of circular knitting machines during yarn changeover and when yarns are moved to inactive positions includes an elastomeric member having deformable when engaged with a flat surface and having pliable surfaces for simultaneously receiving and individually gripping multiple yarns, the member being of silicone rubber having a durometer hardness range of 45-70.

Yarn binder apparatus

Growing community of inventors

Brooklyn, NY, United States of America

Joe F Lee